Focused on Life

Providing new therapies to care-givers for diseases that currently have few or no treatment options with the aim to improve the lives of those faced with rare diseases with high unmet medical needs

Management Team

Under the leadership of Chief Executive Officer, Fintan Keegan, Gentium’s management team includes leaders with expertise in research, clinical, finance, quality, manufacturing and human resources. Gentium is focused on delivering first-to-market therapies to patients with rare diseases.

Senior VP, Commercial Operations

Adrian Haigh joined Gentium in March 2011 as our Senior Vice President, Commercial Operations. He is responsible for establishing our commercial organization and for business development. Prior to joining Gentium, Mr. Haigh served as Regional Vice President, Commercial Operations at Biogen Idec where he managed several affiliates and also the global distributor business. From 2002 to 2007 he held leadership positions at Amgen, including General Manager of Portugal and Scandinavia and Head of the $1.5b International Oncology Franchise. Mr. Haigh’s career also includes management positions with SmithKline Beecham, Schering-Plough, Organon and Novo-Nordisk. He received a Bachelor of Arts with Honours in Economic History from Huddersfield Polytechnic, West Yorkshire, England and a Diploma in Marketing from the Institute of Marketing.

Senior VP Finance, Chief Financial Officer and Chief Operating Officer

Salvatore Calabrese has served as our Chief Financial Officer since December 2010, Senior Vice-President of Finance since February 2010 and our Vice-President of Finance since February 2005. From December 2003 until February 2005, he was an Accounting and Finance Manager for Novuspharma, S.p.A., a development stage biopharmaceutical company focused on the discovery and development of cancer drugs and a subsidiary of Cell Therapeutics, Inc., a public reporting company, which then merged into Cell Therapeautics, Inc. He reported to the Chief Financial Officer of Cell Therapetucs, Inc. and was responsible for cost containment, budgeting, financial reporting and the implementation of Sarbanes-Oxley compliance. From September 1996 until November 2003, Mr. Calabrese was employed by PricewaterhouseCoopers as an accountant and was a Manager in Assurance Business Advisory Services at the time of departure. From October 2000 to June 2003, Mr. Calabrese worked in the Boston, MA office of PricewaterhouseCoopers. He earned a Bachelors' Degree in Economics at the University of Messina and a Masters' Degree in Accounting, Audit and Financial Control at the University of Pavia. He is also a chartered accountant in the Republic of Italy.

Vice President Quality, Qualified Person

Mr. Terenzio Ignoni has served as our Vice President Quality since January 2011 and as Quality Manager since January 2007. From April 2005 to December 2006, as Quality Control Manager, he was in charge of the development and implementation of the Quality Control Department of Gentium SpA which was audited, approved and officially authorized by the Italian Regulatory Agency in February 2007. From September 2002 to March 2005 he was analytical development manager at Zambon Group, facility of Almisano di Lonigo, Italy. From March 2001 to September 2002 he worked in the Quality Control of Biosearch Manufacturing, company specialized in the research, development and manufacturing of antibiotics and antifungal agents. He obtained a degree in Pharmaceutical chemistry and technologies at the University of Turin, Italy. He is also certified Qualified Person according to EU Directive 2001/83/EC and related amendment.

Senior VP and Scientific Director

Giorgio Mosconi joined the Company in June 2013 as our VP Medical Affairs. He has over twenty years of experience in the major pharmaceutical and biotechnology companies in Europe and in the United States. He has developed significant experience covering a variety of executive management positions, from clinical development to areas of the business. After few years of medicine practice, he joined pharma industry holding senior positions at Marion Merrel Dow  ( now Sanofi) in Zurich  and at  BMS in Brussels. He  became  EVP at Biosearch Italian, first Biotech Italian public company, which later became Vicuron where he was SVP of business development based at  corporate headquarter in Philadelphia. Dr. Mosconi is co-author of various scientific papers and important patents ranging among others, i.e. the use of Dalbavacin and Ramoplanin for the prevention and treatment of CDI. Over the years, he has been honored with prestigious awards such as the BMS President Award 1999 and in 2010 was named "Italian protagonist in the world" by the Ministry of Foreign Affairs and in 2013 “Cavaliere della Repubblica Italiana”.